← Back to blog

Clinical Trial Readiness Assessment: A Practical Guide for Biotech Teams

November 8, 2026
Clinical Trial Readiness Assessment: A Practical Guide for Biotech Teams

A clinical trial readiness assessment is a structured check, done before first participant in, of whether your team, sites, systems, documents and money can run the protocol as written. It turns "we think we're ready" into evidence you can score, assign to an owner and review at a go/no-go gate. This guide covers what to assess, when to start, how to find the bottlenecks that stall startup, and how to decide.

Haiphai
Reduce Bottlenecks Before Trial Startup
HaiPhai works with life sciences teams to identify operational bottlenecks and streamline processes such as regulatory drafting and clinical site activation.
Explore HaiPhai

TL;DR

  • Start assessing as soon as a site or program shows interest, and keep going through planning and startup. Don't treat it as a one-time gate.
  • Cover six areas: research team, infrastructure, study management, data collection and management, quality oversight, and ethics and safety.
  • Ask for evidence (SOPs, test results, signed documents), not verbal assurances.
  • Check site finances early. Thin margins, holdbacks and late payments are a common source of delay.
  • Set go/no-go criteria in advance and track each area against them.

Table of Contents

What a readiness assessment actually evaluates

The term covers two related questions. The first is whether your organization is ready to sponsor or run the study. The second is whether each site can conduct it safely, ethically and efficiently. A feasibility assessment, according to guidance from the ANZCA Clinical Trials Network, looks at exactly that: can the trial be conducted safely, ethically and efficiently at a site. It also says the process should begin as soon as interest is expressed and continue through planning and implementation.

That timing matters for biotech teams. Many sponsors run readiness checks only when the protocol is final, which is the point where fixing anything costs the most time. If you run lighter checks earlier and deepen them as the protocol firms up, problems show up while they are still cheap to fix.

A useful assessment has three properties:

  1. It is scored. Every area gets a status (ready, at risk, not ready) with a named owner.
  2. It is evidenced. Each "ready" status points to a document, a test result or a signed record.
  3. It is dated. It ties to a startup timeline, so a gap shows up as a delay in days or weeks, not as a vague worry.

The six domains to cover

An academic framework for assessing clinical trial site readiness groups site readiness practices into six domains. It is a good backbone because it covers more than paperwork. Here is how each domain translates into questions your team can ask.

DomainWhat to askEvidence to collect
Research teamIs the principal investigator available and qualified? Are coordinators, pharmacists and sub-investigators named and trained?CVs, training records, delegation log
InfrastructureDo systems, facilities, and financial and legal functions support this protocol?Equipment lists, system validation, contract and budget status
Study managementWho tracks timelines, enrollment and issues?Study plans, responsibility matrix, meeting cadence
Data collection and managementHow is data captured, reviewed and queried?Data management plan, system access, test results
Quality oversightHow are deviations caught and handled?SOPs, monitoring plan, deviation process
Ethics and safetyAre approvals and safety reporting routes in place?IRB approvals, safety reporting procedures

Notice that finance and legal sit under infrastructure in this framework. Teams that treat contracts and budgets as a separate, later workstream often discover late that a site cannot start for non-clinical reasons.

Look beyond the project plan

A project plan shows tasks and dates. Readiness asks whether the operating environment can carry the work: people, processes, technology, data, support, compliance and governance. A task can be marked complete on the plan while the thing it produced does not work in practice. An SOP exists but nobody has been trained on it. A system is installed but the site has no access. Your assessment should look for those gaps on purpose.

When to run it, and how often

Think in layers rather than one event.

  • Early (concept to protocol draft): a high-level check of sponsor-side capacity, target site types, patient access and budget realism.
  • Site selection: feasibility screening of candidate sites.
  • Pre-activation: a deeper, protocol-specific check on each selected site.
  • Pre-first-participant: a final go/no-go review using the evidence gathered.

The layering also helps sites. A collaborative feasibility model published in the academic literature proposes dividing site feasibility into four phases: Profile, Capability, Performance and Protocol-Specific. The aim is to let sponsors engage sites earlier without asking for the same documentation again and again. Practically, that means a site's general profile and capability can be gathered once, and only protocol-specific questions need to wait for the final protocol.

If your feasibility questionnaire is long and repetitive, that is a readiness problem in its own right. We cover how to tighten these forms in our guide to feasibility questionnaire optimization.

A step-by-step way to run the assessment

1. Define what "ready" means for this study

Write the criteria before you collect answers. For a complex oncology protocol with specialized imaging, readiness looks different from a simple oral-dose study. List the critical-to-quality factors, the things that, if they fail, make the trial results unreliable or participants unsafe, and make sure each maps to a readiness question. Our piece on clinical protocol governance shows how to link those factors to ownership and KPIs.

2. Build the scorecard

Use the six domains above as rows. Add columns for owner, evidence, status, due date and risk if late. Keep it to one page per site where you can. Long scorecards get skimmed.

3. Collect evidence, not assurances

A site that says "our coordinator is trained" has told you very little. A training record tells you more. Make the rule explicit in your request: every "ready" needs an attachment or a reference. It slows the first pass slightly and prevents surprises later.

4. Stress-test the workflows

For technology-dependent studies, validate workflows before the first participant is enrolled. The Digital Medicine Society's guidance on first participant in readiness recommends simulating failure modes, such as connectivity loss or device issues, and documenting how each is resolved. Even for studies with no devices, the idea carries over. Walk through a sample visit, a sample serious adverse event report and a sample drug shipment, and see where the process stalls.

5. Review at a decision gate

Agree go/no-go criteria in advance. A gate meeting should answer three things: which areas are fully evidenced, which carry an accepted risk with a mitigation, and which block startup. A "conditional go" is fine when the condition has an owner and a date.

Documents, processes and systems to confirm before startup

What has to be in place varies by protocol, regulator and sponsor SOPs, so build your list from your own quality system and the regulations that apply to the study. In general, most U.S. startup checks fall into the same buckets:

  • Approvals and agreements: IRB approval for the site, clinical trial agreements and, where applicable, IND status.
  • People: investigator and staff qualifications, role-appropriate training completed before involvement in trial activities, and a record of delegated tasks.
  • Essential records: protocol and amendments, investigator brochure, consent forms, and data and safety plans, filed where the team and monitors can find them.
  • Systems: data capture, safety reporting, and any participant-facing technology, tested and accessible to the right people.
  • Supply and logistics: investigational product handling, lab kits, shipping and storage.

Many teams now keep essential documentation in electronic regulatory binders. Emory University's clinical trials guidebook notes that eReg systems let multiple locations access records and let investigators sign electronically. That helps readiness reviews too, because a reviewer can see what is filed and what is missing without chasing paper.

IRB timing deserves special attention, since a missed submission window can add weeks. Our site readiness checklist walks through the preparation steps that help avoid avoidable review delays.

Materials and quality ownership

Research labs and preclinical support teams that handle reagents or compounds need the same discipline: someone owns the check, and the check is documented. A short, specific example is approving incoming lots against research-use-only lot checks, where certificates of analysis and testing documentation are reviewed before material is released to the bench. The principle holds across a readiness program: a named person, a written criterion and a record.

Technician checks incoming reagent lot documentation

Readiness gaps that delay startup, and how to close them

Site finances

Site economics are an operational issue, not just a contracting one. Academic work on sponsor-site interaction, published in a peer-reviewed journal, describes financial margins at some research sites as exceptionally narrow. It suggests sponsors can help by eliminating holdbacks and making all study payments on time and monthly. If your payment terms are slow, a site may deprioritize your study, which shows up as slow activation and slow enrollment.

A financial readiness review should check: budget approved on both sides, payment schedule agreed, invoicing steps clear, and who at the sponsor answers a payment question.

Unclear ownership

In our experience, the most common pattern behind a missed startup milestone is not a missing document but a missing owner. Two functions each assume the other will chase the contract, or a regulatory step has no named backup when the lead is out. Your scorecard's owner column is the cheapest fix available. Review it every week during activation.

Disconnected information

Site status often lives in several places: a tracker, email threads, a CTMS and a spreadsheet someone keeps privately. When they disagree, the team debates data instead of acting. Pick one source of truth for activation status and make updating it part of the process, not an afterthought.

Bottlenecks you can see only with data

Some delays are structural: a specific contract step that takes the longest at every site, or a handoff between regulatory and clinical operations. To find them, look at cycle times by step across past activations. Our guides on site activation bottlenecks and the broader activation process show how data and parallel work can compress the timeline toward 90 to 120 days. For a more structured screen of candidate sites, see our five-stage site feasibility approach.

Enrollment assumptions

A site can be fully ready operationally and still fail on patient access. Treat enrollment projections as part of the readiness review, and use ranges rather than single numbers. Our article on P10/P50/P90 enrollment forecasts explains how ranges point to the sites that are the real bottleneck.

Tracking progress and making the go/no-go call

A workable tracking rhythm looks like this:

CadenceActivity
WeeklyScorecard review by the study team: new risks, overdue items, owner changes
Every two weeksCross-functional review with regulatory, clinical operations, data management, quality and finance
At each gateFormal go/no-go with documented evidence for each domain

At the gate, decisions should be binary on blockers and explicit on accepted risks. Write down what you decided and why. If you later face an inspection or an audit, that record shows the team thought systematically about readiness. Teams preparing for that scrutiny can use our 8 to 12 week inspection readiness sprint, and our risk register guide shows how to link risks to key risk indicators. If you plan risk-based monitoring, the 90-day setup checklist shows what should be ready before the first monitoring visit.

Our perspective

Most readiness assessments we see fail in the same way. They are built as a form, filled in once, and filed. The real work is operational: who owns each gap, how fast it closes, and whether the next study starts from what this one taught the team.

That is why we start from your strategic goal, such as a filing date, a financing milestone or a first-participant-in target, and work backward to the steps that gate it. Bottlenecks rarely sit where the org chart says they do. They sit in handoffs between regulatory drafting, site activation, contracting and executive sign-off.

Our model is an embedded operating partnership, not a software rollout. We map the bottlenecks first through a diagnostic, then redesign workflows around your scientific and regulatory needs, bring AI into the steps where it helps, and set governance so the gains hold. Our aim is to help clients reclaim as much as 18 months of operational time on the path to approval, which matters for valuation and funding.

A readiness assessment is the natural first move in that work. It gives everyone the same picture of where time is being lost.

John

Where HaiPhai fits

If your readiness review keeps surfacing the same delays, such as slow site activation, regulatory drafting that stretches timelines, or knowledge held in a few people's heads, that is the work our operating partnership is designed for. We begin with an AI Velocity Diagnostic to map where time is lost, then work with your clinical, regulatory and executive teams to redesign and govern those workflows.

Haiphai

See how an engagement works on our partnership page, or read our view on where AI can help in regulatory affairs and what must stay human. If you are weighing a dedicated partner against hiring, our decision framework lays out the criteria.

FAQ

What is the difference between a feasibility assessment and a readiness assessment?

Feasibility asks whether a trial can be run at a given site or in a given setting. Readiness asks whether everything needed is actually in place and tested. In practice they overlap and run in sequence: feasibility screens options early, readiness confirms preparedness before first participant in.

When should a biotech start a readiness assessment?

Earlier than most teams do. Published guidance recommends beginning feasibility as soon as interest is expressed and continuing through planning and implementation. Start with a lighter sponsor-side review at protocol concept, then add site-level depth as sites are selected.

Who should own the assessment?

One accountable lead, usually in clinical operations or program management, with named owners for each domain. Regulatory, quality, data management, finance and legal each own their rows. A single scorecard with one accountable lead prevents the common problem of every function assuming someone else is checking.

What evidence should we ask sites for?

Ask for records that show something is done: training logs, signed agreements, approvals, system access confirmations and test results. A verbal confirmation is a prompt to ask for the record, not a replacement for it. Build the evidence list into your scorecard so sites know what to send.

Can a small biotech do this without a large operations team?

Yes. A one-page scorecard, a weekly review and a clear owner for each domain cover most of the value. As programs grow, an operating partner can add capacity and structure without a permanent hiring commitment.

Sources